Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor^[3] properties^[1]. Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways^[2]. Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells^[3]. IC50 & Target: NF-κB^[3] In Vitro: Zingerone is a nontoxic methoxyphenol with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic properties^[1].
Zingerone (0-2 mM) decreases neruoblastoma cell survival^[3].
Zingerone (0-2 mM) reduces cyclin D1 expression, increases cleavage of caspase-3 and PARP-1 in BE(2)-M17 cells^[3].
In Vivo: Zingerone (50, 100  mg/kg, p.o. daily for 21 days) protects against alloxan-induced diabetes via alleviation of oxidative stress and inflammation in rat^[2].
Zingerone (10 mg/kg, i.p.) inhibits tumor progression through mitotic arrest, failure of cell division, and stimulation of apoptosis^[3].